转胺酶2通过向p53/mTOR轴来促进乳腺癌细胞自
Jiasi Chen1, Mengxin Li2, Juanjuan Mao1
1College of Basic Medical Sciences, the Medical Basic Research Innovation Center of Airway Disease in North China, Key Laboratory of Pathobiology, Ministry of Education, and Department of Pathophysiology, Jilin University, Changchun 130021, China.
转胺酶2 (TGM2) 驱动乳腺癌 (BC) 的生长,并表明预后不佳. 一种TGM2抑制剂,GK921,通过诱导细胞死亡和激活自来抑制瘤生长,突出显示TGM2是BC的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 乳腺癌 (BC) 是女性的主要恶性瘤,需要针对晚期的新型治疗方法.
- 在BC中转质氨酶2 (TGM2) 的高表达与患者预后不佳相关,这表明它在瘤进展中的作用.
研究的目的:
- 为了研究TGM2在BC生长中的作用,并评估TGM2抑制剂的治疗潜力,GK921.1.
- 阐明GK921影响BC细胞的分子机制,包括其对自和细胞死亡的影响.
主要方法:
- 研究了BC中的TGM2表达及其与预后的相关性.
- 评估了TGM2抑制剂GK921对BC细胞系和小鼠模型中的瘤生长的影响.
- 利用RNA干扰 (RNAi) 来降低TGM2的调节,并检查其对自的影响.
- 分析了GK921对p53和mTOR信号通路的影响.
主要成果:
- 高TGM2表达与不良的BC预后有关.
- GK921抑制了TGM2活性,抑制了BC细胞生长,并诱导了自依赖的细胞死亡.
- GK921治疗导致p53水平增加和mTOR表达减少,这是自的一个关键调节器.
- 通过RNAi激活自的TGM2下调.
- 在临床前的小鼠模型中,GK921显著抑制了乳腺瘤的生长.
结论:
- TGM2在乳腺癌的进展中起着重要作用.
- GK921通过向TGM2,抑制瘤生长,并通过自诱导细胞死亡来证明治疗潜力.
- 抑制TGM2是治疗晚期乳腺癌的一个有希望的策略.
更多相关视频
08:07Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
Published on: April 28, 2023
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
The Intrinsic Apoptotic Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
